Table 2.
Characteristics for patients with CMV viremia
| Variable | Patient 1 | Patient 2 | Patient 3 |
|---|---|---|---|
| Age, years | 2.1 | 9.9 | 11.1 |
| Sex | Female | Female | Male |
| Race | Other | Other | Other |
| PIM2 risk of mortality | 8.2 | 5.5 | 0.8 |
| PRISM III score | 15 | 9 | 3.0 |
| Number of comorbid conditions | >5 | 2 | 1 |
| Cancer | No | AML | No |
| Active chemotherapy and leukopenia | No | Yes | No |
| Corticosteroids | Dexamethasone | No | Methylprednisolone |
| Immunomodulator therapy | No | GM-CSF | No |
| Immunoglobulin therapy | No | Yes | No |
| Blood product transfusion | PRBC | PRBC, Platelet, FFP | PRBC, Platelet |
| 28-day mortality | No | No | No |
PIM2, pediatric index of mortality-2; PRISM, pediatric risk of mortality; AML, acute myeloid leukemia; GM-CSF, granulocyte-macrophage colony-stimulating factor; PRBC, packed red blood cell; FFP, fresh frozen plasma